SYNB:NYE-Putnam Biorevolution ETF (USD)

ETF | Others |

Last Closing

USD 29.5599

Change

+0.18 (+0.60)%

Market Cap

USD 5.43M

Volume

193.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SOJE SOJE

+0.39 (+2.03%)

USD 65.72B
JEPI JPMorgan Equity Premium Income..

+0.15 (+0.26%)

USD 33.68B
DFAC Dimensional U.S. Core Equity 2..

+0.34 (+1.07%)

USD 27.49B
DTB DTB

+0.19 (+0.98%)

USD 26.58B
GBTC Grayscale Bitcoin Trust (BTC)

+4.04 (+7.37%)

USD 23.75B
JPST JPMorgan Ultra-Short Income ET..

+0.03 (+0.06%)

USD 23.09B
SGOV iShares® 0-3 Month Treasury B..

+0.02 (+0.02%)

USD 20.81B
AVUV Avantis® U.S. Small Cap Value..

+0.51 (+0.55%)

USD 11.25B
DFUV Dimensional US Marketwide Valu..

+0.21 (+0.52%)

USD 10.54B
DFAT Dimensional U.S. Targeted Valu..

+0.44 (+0.81%)

USD 9.93B

ETFs Containing SYNB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.58% 58% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.58% 48% F 49% F
Trailing 12 Months  
Capital Gain 7.24% 53% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.24% 40% F 45% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.53% 67% D+ 50% F
Dividend Return 2.53% 60% D- 40% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.12% 78% C+ 93% A
Risk Adjusted Return 49.39% 73% C 74% C
Market Capitalization 5.43M 14% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.